- Metal-Free and Redox-Neutral Conversion of Organotrifluoroborates into Radicals Enabled by Visible Light
-
Converting organoboron compounds into the corresponding radicals has broad synthetic applications in organic chemistry. To achieve these transformations, various strong oxidants such as Mn(OAc)3, AgNO3/K2S2O8, and Cu(OAc)2, in stoichiometric amounts are required, proceeding by a single-electron transfer mechanism. Established herein is a distinct strategy for generating both aryl and alkyl radicals from organotrifluoroborates through an SH2 process. This strategy is enabled by using water as the solvent, visible light as the energy input, and diacetyl as the promoter in the absence of any metal catalyst or redox reagent, thereby eliminating metal waste. To demonstrate its synthetic utility, an efficient acetylation to prepare valuable aryl (alkyl) methyl ketones is described and applications to construct C?C, C?I, C?Br, and C?S bonds are also feasible. Experimental evidence suggests that triplet diacetyl serves as the key intermediate in this process.
- Liu, Wenbo,Liu, Peng,Lv, Leiyang,Li, Chao-Jun
-
supporting information
p. 13499 - 13503
(2018/09/25)
-
- Imidazopyrazine compound, and preparation method and application thereof
-
The invention belongs to the technical field of medicines and relates to an imidazopyrazine compound, and a preparation method and an application thereof. Specifically, the invention relates to a compound with a structure shown in a formula (I) defined in the specification, a pharmaceutically acceptable salt of the compound, a stereisomer of the compound or a prodrug of the compound, and an application of the compound, the pharmaceutically acceptable salt of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of drugs. The drugs are used for preventing and/or treating diseases and/or symptoms, related to the over-activity of Bruton's tyrosine kinases, of subjects. The invention furthermore relates to an application of the compound, pharmaceutically acceptable salts of the compound, the stereisomer of the compound or the prodrug of the compound to the preparation of preparations. The preparations are used for reducing or inhibiting the activity of the Bruton's tyrosine kinases in cells.
- -
-
-